UTHR UNITED THERAPEUTICS Corp

NEUTRAL Impact: 3/10 Insider Cluster (3 insiders)
Horizon days Filed Jun 4, 2026 Processed 2d 1h ago
Insider cluster: 3 insiders, $1.1M total

Price Chart

Loading chart...

Executive Summary

Three top executives at United Therapeutics (CEO, CFO, General Counsel) collectively sold $1.11M in open-market shares over a 5-day window, all following derivative exercises at deep in-the-money strike prices. The sales are consistent with routine post-vesting tax and diversification activity — the total represents ~0.005% of the $23.3B market cap, well below the materiality threshold for informational selling. The cluster is amplified by the cross-filing context (cluster-insider-trades + cluster-earnings-context), but the absolute dollar value is trivial for a company of this size.

Key Financial Metrics

Direction
selling
Total Value
$1.1M
Insiders
3

Actionable Insight

This cluster is routine post-vesting selling by top executives — the dollar amounts are negligible for a $23B company. The simultaneous option exercises suggest a scheduled vesting event rather than a coordinated bearish signal. No actionable trading signal here; monitor the next 10-Q for any fundamental changes.

Key Facts

  • CEO Martine Rothblatt sold 2,926 shares total across 3 days for ~$1.58M, all after exercising options at $146.03
  • CFO James Edgemond sold 1,440 shares for ~$785K after exercising options at $117.76
  • General Counsel Paul Mahon sold 200 shares for ~$108K after exercising options at $146.03
  • Total open-market sales: $1.11M, representing ~0.005% of UTHR's $23.3B market cap
  • All three insiders simultaneously exercised options — a pattern consistent with scheduled vesting/expiration, not coordinated bearish conviction
  • Historical performance on UTHR reports shows a 17% win rate at T+20 with avg alpha of -6.51%, suggesting the model has over-scored this ticker

Financial Impact

Total insider sales of $1.11M are immaterial relative to $23.3B market cap (0.005%)

insider ownershipdilution

Risk Factors

  • Insider selling at the C-suite level, even if routine, can weigh on sentiment if the stock is at all-time highs
  • The historical calibration shows UTHR reports have underperformed at T+20, suggesting the stock may face headwinds regardless of this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (22 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1780608665703
49 reports for UTHR
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+60▲ +5.53%Feb 25, 2026
Filters
Rows
Reports for UTHR — sortable, filterable
Type Now
Jun 5, 2026
1d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
Jun 4, 2026
2d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+20
Jun 4, 2026
2d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
Jun 3, 2026
3d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
May 29, 2026
8d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
May 28, 2026
9d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+20
May 27, 2026
10d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
May 26, 2026
11d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+20
May 26, 2026
11d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
May 22, 2026
15d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
Showing 10 of 49

US Market Status

Market Closed — Opens Mon (14h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access